Hormone Treatment Linked to Development of Aggressive Cancer
|
By LabMedica International staff writers Posted on 06 Dec 2018 |
|
Image: Graph shows elevated activity of a transcription-factor network that includes the molecule onecut2 in tumors of patients whose prostate cancer resisted hormone therapy (above purple bar) compared with other types (Photo courtesy of the Nature Publishing Group).
A team of cancer researchers has identified a gene that promotes the growth and spread of the most aggressive type of prostate cancer.
While many forms of prostate cancer require little or no treatment, the aggressive type that spreads to other parts of the body and resists hormone therapy is usually fatal with only a third of such patients living for five years after diagnosis.
Previous studies have shown that treatment of prostate cancer (PC) by androgen suppression promoted the emergence of aggressive variants that were androgen receptor (AR) independent. In a paper published in the November 26, 2018, online edition of the journal Nature Medicine, investigators at Cedars-Sinai Medical Center (Los Angeles, CA, USA) identified the transcription factor ONECUT2 (OC2) as a master regulator of AR networks in metastatic castration-resistant prostate cancer (mCRPC).
The ONECUT2 (one cut homeobox 2) gene encodes a member of the onecut family of transcription factors, which are characterized by a cut domain and an atypical homeodomain. The OC2 protein binds to specific DNA sequences and stimulates expression of target genes, including genes involved in melanocyte and hepatocyte differentiation.
In the current study, OC2 was found to act as a survival factor in mCRPC models, suppressing the AR transcriptional program by direct regulation of AR target genes. It also activated genes associated with neural differentiation and progression to lethal disease. Furthermore, OC2 was active in a substantial subset of human prostate adenocarcinoma and neuroendocrine tumors.
Following up, the investigators identified the compound CSRM617, which counteracted the action of onecut2. They showed that CSRM617 significantly reduced the size of prostate cancer metastases in mice.
"We need fresh strategies to prevent prostate cancer from turning deadly for the thousands of men whose disease metastasizes and withstands hormone therapy," said senior author Dr. Michael Freeman, professor of surgery and biomedical sciences at Cedars-Sinai Medical Center. "Our research suggested that onecut2 is a master regulator of lethal prostate cancer that may be a useful therapeutic target in up to a third of patients whose cancer spreads and evades hormone therapy."
Related Links:
Cedars-Sinai Medical Center
While many forms of prostate cancer require little or no treatment, the aggressive type that spreads to other parts of the body and resists hormone therapy is usually fatal with only a third of such patients living for five years after diagnosis.
Previous studies have shown that treatment of prostate cancer (PC) by androgen suppression promoted the emergence of aggressive variants that were androgen receptor (AR) independent. In a paper published in the November 26, 2018, online edition of the journal Nature Medicine, investigators at Cedars-Sinai Medical Center (Los Angeles, CA, USA) identified the transcription factor ONECUT2 (OC2) as a master regulator of AR networks in metastatic castration-resistant prostate cancer (mCRPC).
The ONECUT2 (one cut homeobox 2) gene encodes a member of the onecut family of transcription factors, which are characterized by a cut domain and an atypical homeodomain. The OC2 protein binds to specific DNA sequences and stimulates expression of target genes, including genes involved in melanocyte and hepatocyte differentiation.
In the current study, OC2 was found to act as a survival factor in mCRPC models, suppressing the AR transcriptional program by direct regulation of AR target genes. It also activated genes associated with neural differentiation and progression to lethal disease. Furthermore, OC2 was active in a substantial subset of human prostate adenocarcinoma and neuroendocrine tumors.
Following up, the investigators identified the compound CSRM617, which counteracted the action of onecut2. They showed that CSRM617 significantly reduced the size of prostate cancer metastases in mice.
"We need fresh strategies to prevent prostate cancer from turning deadly for the thousands of men whose disease metastasizes and withstands hormone therapy," said senior author Dr. Michael Freeman, professor of surgery and biomedical sciences at Cedars-Sinai Medical Center. "Our research suggested that onecut2 is a master regulator of lethal prostate cancer that may be a useful therapeutic target in up to a third of patients whose cancer spreads and evades hormone therapy."
Related Links:
Cedars-Sinai Medical Center
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read more
Molecular Diagnostics
view channel
RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more
First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
Many men with early-stage prostate cancer receive stereotactic body radiotherapy (SBRT), a highly precise form of radiation treatment that is completed in just five sessions. Compared to traditional radiation,... Read more
Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
Anti-myelin-associated glycoprotein (MAG) antibodies serve as markers for an autoimmune demyelinating disorder that affects the peripheral nervous system, leading to sensory impairment. Anti-MAG-IgM antibodies... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
Handheld Device Deliver Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Pathology
view channel
Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
Myasthenia gravis, an autoimmune disease, leads to muscle weakness that can affect a range of muscles, including those needed for basic actions like blinking, smiling, or moving. Researchers have long... Read more
AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor.... Read more
Technology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read more
Industry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
